Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
291. |
ECCT/19/06/02 | The A-PLUS study Prevention of Maternal and Neonatal Death/Infections with a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-Income Countries): a Randomized Controlled Trial |
Principal Investigator(s) 1. Prof Fabian Esamai Omoding Esamai Site(s) in Kenya 1. Alupe, Sirisia, Bokoli (Bung\'oma county) 2. Nambale, Nasewa, Lukolis, Khunyangu (Busia county) 3. Mumias (Kakamega county) |
View |
292. |
ECCT/19/06/01 | EPI 003 A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa. |
Principal Investigator(s) 1. Walter Otieno Site(s) in Kenya 1. Ahero clinical triasl unit (Kisumu county) 2. KEMI CDC (Siaya county) |
View |
293. |
ECCT/19/05/03 | SEARCH Supportive Care and Antibiotics for Severe Pneumonia among Hospitalised Children |
Principal Investigator(s) 1. Ambrose Agweyu Site(s) in Kenya 1. Mama Lucy Kibaki Hospital (Nairobi City county) 2. Kiambu County Referral Hospital (Kiambu county) 3. Machakos County Referral Hospital (Machakos county) 4. Embu County Referral Hospital (Embu county) 5. Naivasha County Hospital (Nakuru county) 6. Bungoma County Referral Hospital (Bung\'oma county) 7. Busia County Referral Hospital (Busia county) 8. Kitale County Referral Hospital (Trans Nzoia county) 9. Kisumu East Hospital (Kisumu county) 10. Kakamega County Referral Hospital, Kenya (Kakamega county) |
View |
294. |
ECCT/19/05/02 | ETNA EVALUATION OF TECHNOLOGIES FOR NEONATES IN AFRICA |
Principal Investigator(s) 1. PROF WILLIAM MAINA MACHARIA Site(s) in Kenya 1. AGA KHAN UNIVERSITY HOSPITAL (Nairobi City county) 2. PUMWANI MATERNITY HOSPITAL (Nairobi City county) |
View |
295. |
ECCT/19/05/01 | A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults |
Principal Investigator(s) 1. Omu Anzala Site(s) in Kenya KAVI-ICR KNH SITE |
View |